GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/31ncLKO
via IFTTT